AI-ACCELERATED DRUG DISCOVERY

Focused On-demand Library for Tectonic-3

Available from Reaxense
Predicted by Alphafold

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.

From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Our collaborator, Reaxense, aids in their synthesis and provision.

The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.

We utilise our cutting-edge, exclusive workflow to develop focused libraries.

 Fig. 1. The sreening workflow of Receptor.AI

Our strategy employs molecular simulations to explore an extensive range of proteins, capturing their dynamics both individually and within complexes with other proteins. Through ensemble virtual screening, we address proteins' conformational mobility, uncovering key binding sites at both functional regions and remote allosteric locations. This comprehensive investigation ensures a thorough assessment of all potential mechanisms of action, with the goal of discovering innovative therapeutic targets and lead molecules across across diverse biological functions.

Several key aspects differentiate our library:

  • Receptor.AI compiles an all-encompassing dataset on the target protein, including historical experiments, literature data, known ligands, and structural insights, maximising the chances of prioritising the most pertinent compounds.
  • The platform employs state-of-the-art molecular simulations to identify potential binding sites, ensuring the focused library is primed for discovering allosteric inhibitors and binders of concealed pockets.
  • Over 50 customisable AI models, thoroughly evaluated in various drug discovery endeavours and research projects, make Receptor.AI both efficient and accurate. This technology is integral to the development of our focused libraries.
  • In addition to generating focused libraries, Receptor.AI offers a full range of services and solutions for every step of preclinical drug discovery, with a pricing model based on success, thereby reducing risk and promoting joint project success.

partner

Reaxense

upacc

Q6NUS6

UPID:

TECT3_HUMAN

Alternative names:

-

Alternative UPACC:

Q6NUS6; A6NIC8; B0QZ90; B4DR81; Q6P7P3; Q6UW27; Q6ZQQ0; Q8N7K1; Q8NBQ0; Q96GF7; Q9Y3U1

Background:

Tectonic-3, encoded by the gene with accession number Q6NUS6, plays a crucial role in tissue-specific ciliogenesis and may influence ciliary membrane composition. It is also implicated in apoptosis regulation and is essential for signal transduction via the sonic hedgehog (Shh) signaling pathway.

Therapeutic significance:

Given its involvement in orofaciodigital syndrome 4 and Joubert syndrome 18, understanding the role of Tectonic-3 could open doors to potential therapeutic strategies targeting these genetic disorders. The protein's function in the Shh signaling pathway suggests avenues for drug discovery aimed at modulating this critical developmental and pathological signaling cascade.

Looking for more information on this library or underlying technology? Fill out the form below and we'll be in touch with all the details you need.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.